They say huge paychecks were awarded to executives as backlash from consumers and the U.S. government escalated over prices Mylan charged for its EpiPen emergency allergy treatment. Lawmakers challenged Mylan last year for its EpiPen pricing, which has climbed more than 500 percent since 2007. Mylan said in an emailed statement Wednesday that its board has overseen a consistent strategy that creates long-term value for its shareholders. The funds claim control of about 4.3 million Mylan shares. Shares of Mylan slipped 23 cents to $39.13 in early trading with all major U.S. markets trading down on rising political turmoil.

Source: ABC News May 31, 2017 13:03 UTC